Johnson & Johnson (JNJ) continues to be a driving force in the bio-tech market with multiple significant developments. The pharmaceutical powerhouse gained U.S. FDA approval for TECVAYLI® and DARZALEX FASPRO® for tackling Relapsed/Refractory Multiple Myeloma, thereby potentially setting a new treatment standard. JNJ also launched a direct-to-consumer sales website, expanding accessibility and contributed more than $1 billion to establish a next-gen cell therapy manufacturing facility in Pennsylvania. Despite facing a $65 million settlement for a Tracleer antitrust class action, JNJ has caught investor's attention. It attained significant stock holdings with multiple entities such as HUB Investment Partners, Guardian Capital, and others. JNJ's stock has seen considerable growth as well, with a 60% gain and continued growth predictions for 2026. A potential $20 billion orthopaedics unit sale, collaboration with the New York Jets on health promotion, and a surge in stock ownership highlight JNJ's momentum. Following FDA approval for its new Multiple Myeloma treatment and positive trials, the company's forecasted 2026 profit surpasses Wall Street's estimate. Lastly, JNJ received U.S. FDA Priority Review for TAR-200 NDA in high-risk non-muscle invasive bladder cancer.
Johnson Johnson JNJ News Analytics from Wed, 18 Jun 2025 07:00:00 GMT to Sat, 07 Mar 2026 12:30:45 GMT -
Rating 8
- Innovation 6
- Rumor 2
